Basic Information
M-M-R II VACCINE
INJECTION, POWDER, FOR SOLUTION
Regulatory Information
SIN02056P
June 24, 1988
Prescription Only
Therapeutic
SUBCUTANEOUS
August 10, 2023
May 30, 2025
XJ07BD52
Company Information
MSD PHARMA (SINGAPORE) PTE. LTD.
MSD PHARMA (SINGAPORE) PTE. LTD.
Active Ingredients
Strength: min 1000 CCID50/0.5 ml
Strength: min 12500 CCID50/0.5ml
Strength: min 1000 CCID50/0.5 ml
Detailed Information
Contraindications
**CONTRAINDICATIONS** Hypersensitivity to any component of the vaccine, including gelatin. Do not give M-M-R II to pregnant females; the possible effects of the vaccine on fetal development are unknown at this time. If vaccination of postpubertal females is undertaken, pregnancy should be avoided for one month following vaccination (see PRECAUTIONS, Pregnancy – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Anaphylactic or anaphylactoid reactions to neomycin (each dose of reconstituted vaccine contains approximately 25 mcg of neomycin). Any febrile respiratory illness or other active febrile infection. Active untreated tuberculosis. Patients receiving immunosuppressive therapy. This contraindication does not apply to patients who are receiving corticosteroids as replacement therapy, e.g., for Addison’s disease. Individuals with blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems. Primary and acquired immunodeficiency states, including patients who are immunosuppressed in association with AIDS or other clinical manifestations of infection with human immunodeficiency viruses; cellular immune deficiencies; and hypogammaglobulinemic and dysgammaglobulinemic states. Measles inclusion body encephalitis (MIBE), pneumonitis and death as a direct consequence of disseminated measles vaccine virus infection have been reported in severely immunocompromised individuals inadvertently vaccinated with measles-containing vaccine. Individuals with a family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated.
Indication Information
**INDICATIONS** M-M-R II is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months of age or older (see DOSAGE AND ADMINISTRATION). There is some evidence to suggest that infants who are born to mothers who had wild-type measles and who are vaccinated at less than one year of age may not develop sustained antibody levels when later revaccinated. The advantage of early protection must be weighed against the chance for failure to respond adequately on reimmunization. Infants who are less than 12 months of age may fail to respond to the measles component of the vaccine due to presence in the circulation of residual measles antibody of maternal origin; the younger the infant, the lower the likelihood of seroconversion. In geographically isolated or other relatively inaccessible populations for whom immunization programs are logistically difficult, and in population groups in which wild-type measles infection may occur in a significant proportion of infants before 15 months of age, it may be desirable to give the vaccine to infants at an earlier age. Infants vaccinated under these conditions at less than 12 months of age should be revaccinated after reaching 12 to 15 months of age.